Welcome to our dedicated page for Ehave news (Ticker: EHVVF), a resource for investors and traders seeking the latest updates and insights on Ehave stock.
The Ehave Inc. (EHVVF) news feed on Stock Titan aggregates company communications and related updates that describe its evolution into an applied artificial intelligence platform operator. Recent press releases highlight Ehave’s acquisition of AIHeadHunter, an AI-powered recruitment platform designed to automate and streamline executive search and talent sourcing through advanced data analysis. These announcements provide insight into how Ehave is repositioning itself around data-driven technology assets and AI-enabled business models.
News linked to Ehave also frequently references its subsidiary AIBotics, Inc. (traded as AIBT), which is described as a developer and manager of AI- and robotics-enhanced technologies. AIBotics press releases cover topics such as the development and pilot deployment of the Phill Robot™ massage robot, the Milkyway smart refrigerator, and partnerships aimed at distributing service robots in markets like Israel and Jamaica. These items illustrate how Ehave’s subsidiary is working with AI, robotics, and agentic AI concepts to build products and platforms for wellness, service environments, and intelligent automation.
Investors and observers using this news page can review how Ehave describes its strategic realignment, including its focus on incubating scalable AI platforms and structuring transactions to support that shift. Coverage includes acquisition terms for AIHeadHunter, descriptions of the technology licensed for that platform, and statements about Ehave’s plans to fund and launch enterprise pilots. For AIBotics, the news flow includes product development milestones, collaboration agreements for UI/UX and operating platforms, and early commercialization efforts such as pilot programs in fitness and wellness facilities.
By following the EHVVF news page, readers can see how Ehave communicates its progress on AIHeadHunter, its relationship with AIBotics, and its broader approach to applied AI and robotics. The articles provide context on the company’s stated objectives, the markets it is targeting through its platforms, and the partnerships it reports as part of its growth plans.
Mycotopia Therapies Inc., a subsidiary of Ehave (OTC: EHVVF), has announced its corporate rebranding to AIBiotics Inc. with a new trading symbol AIBT, effective February 3, 2025. The company, which develops AI and robotics-enhanced technologies, focuses on scaling businesses across healthcare, manufacturing, and logistics sectors.
Recently, AIBiotics signed a letter of intent to acquire DigiTrax Entertainment Inc. in a $40 million deal, which includes seven U.S. patents in music AI technology, a $9 million music catalog, and strategic licensing agreements with major publishers.
AIBotics, a subsidiary of Ehave (EHVVF), has signed a letter of intent to acquire DigiTrax Entertainment in a $40 million transaction. The deal includes seven U.S. patents in music AI, a $9 million music catalog, and licensing agreements with leading publishers. DigiTrax's last funding round valued the company at $32 million.
The acquisition, targeted to close by February 28, 2025, will position DigiTrax as an AIBotics subsidiary. DigiTrax shareholders will receive newly designated preferred stock, common stock, and cash consideration. DigiTrax CEO Joseph Vangieri will retain his position and join AIBotics' board.
DigiTrax operates through three divisions: AI Innovation (featuring the KR38R platform), Karaoke Interactive Digital Media Platform, and Music Catalog Services. The company's AI technology is integrated with major digital audio workstations and has been adopted by platinum artists and major labels.
Ehave (OTC Pink: EHVVF) has announced its return to current SEC filing status and resumed trading on the OTC Pink Market. The company's existing shareholders will find their shares quoted on the OTC Pink Market without requiring any additional action. CEO Ben Kaplan emphasized his commitment to shareholders and expressed confidence in moving the company in a new direction in 2025. This development marks a significant milestone in the company's efforts to maintain transparency, regulatory compliance, and protect shareholder value.
Ehave, Inc. (EHVVF) has successfully completed phase one of its study with the University of Melbourne to investigate hallucinogen-persisting perception disorder (HPPD), a condition that may arise from psychedelics. The study aims to identify biomarkers that help determine individuals at risk of developing HPPD. Preliminary results show a significant occurrence of visual disturbances among participants, indicating potential links to anxiety and depression. Ehave plans to expand the research to include a broader participant base from the HPPD community, targeting the development of effective therapeutic solutions.
Ehave, Inc. announced FDA approval for its clinical study focusing on low-dose intravenous ketamine infusions for patients with Major Depression Disorder (MDD). The study, which involves 35 participants with inadequate responses to existing antidepressants, aims to analyze EEG changes during and after treatment. This marks a pivotal step in exploring ketamine's potential as a treatment for MDD, especially given the growing global prevalence of depression. Ehave seeks to address the limitations of current pharmacological options with its innovative approach.
Ehave, Inc. (OTC Pink: EHVVF) issued a shareholder letter detailing achievements in 2022 amid economic challenges, including inflation and rising interest rates. The company highlighted a $380 million triangular merger involving its subsidiary, Mycotopia Therapies, aimed at NASDAQ trading approval. Key milestones included the acquisition of Rejuv IV, now KetaDASH, which provides at-home ketamine treatments. Ehave also launched MetaHealthU, a platform for patient data integration, and MetaHealthYuru, an AI-driven mental health monitor. The company plans to expand its subsidiaries in 2023.
Ehave, Inc. (OTC Pink: EHVVF) announced that its KetaDASH subsidiary will receive its KetaDASH Mobile Unit in Miami Beach, Florida, on June 10, 2022. This custom medical van will facilitate in-home Ketamine IV treatments, providing real-time health data to enhance clinical outcomes. KetaDASH has already begun operations in Sacramento and San Francisco, offering managed services to streamline physician practices and improve patient care. CEO Ben Kaplan emphasized ketamine's potential for treating various psychological conditions, showcasing the company's commitment to innovative healthcare solutions.
Ehave, Inc. (EHVVF) has announced that its subsidiary, KetaDASH, will utilize precision medicine in psychedelic-assisted therapy through a partnership with HaluGen Life Sciences. This collaboration will employ a genetic testing kit to assess patients' genetic profiles and risk factors. The aim is to personalize treatment based on individual genetic variations, particularly focusing on gene mutations that influence responses to ketamine and other psychedelics. This innovative approach positions KetaDASH as a pioneer in integrating genetics into psychedelic therapy, enhancing patient outcomes and differentiating the company in a competitive market.
Ehave, Inc. (OTC Pink: EHVVF) has disclosed its ownership of approximately 9,793,754 shares in Mycotopia Therapies, valued over $24 million. The company announced a triangular merger with Ei.Ventures, targeting completion by July 30, 2022. This merger aims to establish PSLY.COM, focusing on mental health solutions leveraging psychoactive compounds and technology. Ehave’s stake in Mycotopia is valued at over $0.10 per share, and the merger could potentially benefit shareholders by monetizing existing assets while integrating new opportunities in mental health therapy.
Ehave, Inc. (OTC Pink: EHVVF) has announced its mobile application platform, MetaHealthU, will focus on understanding and curing hallucinogen-persisting perception disorder (HPPD). Partnering with the University of Melbourne, Ehave aims to collect data and biomarkers for HPPD research. The app empowers users to manage their health data securely, leveraging blockchain technology for improved privacy and efficiency. A pilot study for HPPD is set to begin in mid-2022. Ehave aims to lead in mitigating negative side effects of psychedelic treatments by analyzing genetic predispositions related to HPPD.